Literature DB >> 12187461

Initial rightward orienting bias in clinical tasks: normal subjects and right hemispheric stroke patients with and without neglect.

Maarit J Jalas1, Arja B Lindell, Teea Brunila, Olli Tenovuo, Heikki Hämäläinen.   

Abstract

In order to develop the diagnosis of hemi-inattention in patients with right hemispheric cerebrovascular accident (RCVA), the initial starting point of cancellation performance was studied in seven commonly used visual cancellation tasks, an Object Finding task, and a blindfold Tactuo-motor search task. The subject groups consisted of 34 patients with RCVA and 31 healthy subjects. Patients were divided into groups of contralateral neglect and no neglect. One additional case of ipsilesional neglect and one of nonlateralised attentional disorder in relation to early orienting bias, are reported. Patients with contralateral neglect showed a strong tendency to start their cancellation performance on the right. Also, half of the nonneglect patient group demonstrated right bias in initiating their cancellation performance, suggesting the presence of a subclinical hemi-inattention group. Contrary to expectations, also a small proportion of normal subjects were right-biased. Task dependent differences in the assessment of early rightward orienting bias were found.

Entities:  

Mesh:

Year:  2002        PMID: 12187461     DOI: 10.1076/jcen.24.4.479.1036

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  2 in total

Review 1.  Spatial neglect: clinical and neuroscience review: a wealth of information on the poverty of spatial attention.

Authors:  John C Adair; Anna M Barrett
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

2.  The Computerized Table Setting Test for Detecting Unilateral Neglect.

Authors:  Seok Jong Chung; Eunjeong Park; Byoung Seok Ye; Hye Sun Lee; Hyuk-Jae Chang; Dongbeom Song; Young Dae Kim; Ji Hoe Heo; Hyo Suk Nam
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.